The estimated Net Worth of Robert L Md Zerbe is at least $2.1 Millón dollars as of 1 May 2024. Robert Zerbe owns over 3,200 units of Vericel Corp stock worth over $1,162,202 and over the last 10 years he sold VCEL stock worth over $687,354. In addition, he makes $253,085 as Independent Chairman of the Board at Vericel Corp.
Sign up
Robert Zerbe VCEL stock SEC Form 4 insiders trading
Robert has made over 17 trades of the Vericel Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 3,200 units of VCEL stock worth $139,840 on 1 May 2024.
The largest trade he's ever made was exercising 30,000 units of Vericel Corp stock on 23 November 2020 worth over $97,500. On average, Robert trades about 3,626 units every 84 days since 2015. As of 1 May 2024 he still owns at least 26,595 units of Vericel Corp stock.
You can see the complete history of Robert Zerbe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Zerbe biography
Dr. Robert L. Zerbe, M.D., is an Independent Chairman of the Board of the company. Dr. Zerbe is a director since January 2006 and the Chairman of our Board of Directors since October 2012, was, until July 2016, the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture-backed drug development company which he co-founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies including Eli Lilly and Company (from 1982 to 1993) and Pfizer (formerly Parke-Davis) (from 1993 to 2000). During his tenure at Eli Lilly, Dr. Zerbe's clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs. He joined Parke-Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development. In this capacity he led the clinical development programs for a number of key products, including Lipitor® and Neurontin®. Dr. Zerbe received his M.D. from the Indiana University School of Medicine, and has completed post-doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health. He also serves on the board of directors of Metabolic Solutions Development Company and Cirius Therapeutics, both private companies focusing on metabolic diseases.
What is the salary of Robert Zerbe?
As the Independent Chairman of the Board of Vericel Corp, the total compensation of Robert Zerbe at Vericel Corp is $253,085. There are 7 executives at Vericel Corp getting paid more, with Dominick Colangelo having the highest compensation of $5,385,530.
How old is Robert Zerbe?
Robert Zerbe is 69, he's been the Independent Chairman of the Board of Vericel Corp since 2012. There are no older and 14 younger executives at Vericel Corp.
What's Robert Zerbe's mailing address?
Robert's mailing address filed with the SEC is C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE, MA, 02139.
Insiders trading at Vericel Corp
Over the last 10 years, insiders at Vericel Corp have traded over $9,831,645 worth of Vericel Corp stock and bought 890 units worth $10,297 . The most active insiders traders include Dominick Colangelo, Gerard J Michel y Kevin F Mclaughlin. On average, Vericel Corp executives and independent directors trade stock every 17 days with the average trade being worth of $567,401. The most recent stock trade was executed by Steven C Gilman on 4 September 2024, trading 5,000 units of VCEL stock currently worth $18,700.
What does Vericel Corp do?
about vericel founded in 1989, vericel (formerly aastrom biosciences), is dedicated to the development of patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. the company markets two cell therapy products in the united states, carticel® (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee and epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. vericel is also developing maci, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-t, a patient specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy (dcm). to fulfill vericel’s mission of helping people with severe diseases and conditions rea
What does Vericel Corp's logo look like?
Complete history of Robert Zerbe stock trades at Vericel Corp
Vericel Corp executives and stock owners
Vericel Corp executives and other stock owners filed with the SEC include:
-
Dominick Colangelo,
President, Chief Executive Officer, Director -
Michael Halpin,
Chief Operating Officer -
Dominick C. Colangelo Esq.,
CEO, Pres & Director -
Michael Halpin,
Chief Operating Officer -
Dr. Jonathan M. Hopper FRCSEd., M.B. Ch.B.,
Chief Medical Officer -
Dr. Jonathan M. Hopper,
Chief Medical Officer -
Sean C. Flynn,
VP, Gen. Counsel & Sec. -
Robert Zerbe,
Independent Chairman of the Board -
Alan Rubino,
Independent Director -
Kevin McLaughlin,
Independent Director -
Heidi Hagen,
Independent Director -
Steven Gilman,
Independent Director -
Paul Wotton,
Independent Director -
Sandra Pennell,
Principal Financial Officer and Principal Accounting Officer -
Jonathan Siegal,
Principal Accounting Officer, VP & Corp. Controller -
Roland DeAngelis,
Sr. VP of Commercial Operations -
Heidi Hassen,
VP of HR -
Patrick J. Fowler,
Sr. VP of Corp. Devel. & Strategy -
Eric Burns,
Exec. Director of Financial Planning and Analysis & Investor Relations -
Joseph Anthony Mara Jr.,
CFO, Principal Accounting Officer & Treasurer -
Capital Management Lp Conso...,
-
Daniel Orlando,
Chief Operating Officer -
Gerard J Michel,
CFO and VP, Corp. Development -
Nelson M Sims,
Director -
Lisa Wright,
-
Joseph Anthony Jr Mara,
Chief Financial Officer -
Jonathan Siegal,
Principal Accounting Officer -
Jonathan Mark Hopper,
Chief Medical Officer -
Sean C. Flynn,
Chief Legal Officer